These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3213197)

  • 21. Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments.
    Jauhiainen K; Rintala E
    Ann Chir Gynaecol Suppl; 1993; 206():31-8. PubMed ID: 8291866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?
    Sylvester RJ
    Eur Urol; 2007 Oct; 52(4):951-3; discussion 953-4. PubMed ID: 17374437
    [No Abstract]   [Full Text] [Related]  

  • 24. [Minimally invasive therapy for bladder and prostate cancer].
    Uchida T; Ohori M; Egawa S
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1094-8. PubMed ID: 11525024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G
    Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The prevention of recurrences of surface bladder cancer by BCG vaccinal immunotherapy].
    Matveev BP; Kariakin OB; Safiullin KN; Figurin KM; Levi DT; Vatin OE
    Urol Nefrol (Mosk); 1993; (5):27-9. PubMed ID: 8310581
    [No Abstract]   [Full Text] [Related]  

  • 27. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
    Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
    Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is intravesical chemotherapy for superficial bladder cancer still justified?
    Okeke AA; Probert JL; Gillatt DA; Schwaibold H
    BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
    [No Abstract]   [Full Text] [Related]  

  • 30. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
    Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
    Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
    [No Abstract]   [Full Text] [Related]  

  • 31. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
    Yamada Y; Washida H; Tozawa K; Honma H; Kang K
    Hinyokika Kiyo; 1994 Jul; 40(7):575-9. PubMed ID: 8085517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prophylactic effects of zhuling and BCG on postoperative recurrence of bladder cancer].
    Yang DA; Li SQ; Li XT
    Zhonghua Wai Ke Za Zhi; 1994 Jul; 32(7):433-4. PubMed ID: 7842985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definition and management of patients with bladder cancer who fail BCG therapy.
    Martin FM; Kamat AM
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):815-20. PubMed ID: 19496718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
    Bretheau D; Lechevallier E; Rossi D; Albert P; de Fromont M; Coulange C
    Prog Urol; 1993; 3(4):608-17. PubMed ID: 8401621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer].
    Zhang S; Li H; Cheng H
    Zhonghua Wai Ke Za Zhi; 1995 May; 33(5):304-6. PubMed ID: 7587700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer.
    Rosenbaum RS; Park MC; Fleischmann J
    Urology; 1996 Feb; 47(2):208-11. PubMed ID: 8607236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.